FibroBiologics, Inc. issued a letter to shareholders summarising its achievements in 2025 and strategic focus for 2026 as it advances its fibroblast-based therapeutic platform aimed at chronic diseases, wound healing and regeneration. The company said it is driving innovation in fibroblast cells and fibroblast-derived materials with more than 270 issued and pending patents worldwide covering areas such as wound healing, orthopedics, multiple sclerosis, psoriasis, cancer and human longevity.
Key corporate milestones in 2025 included the unveiling of a new 10,000+ sq ft laboratory and in-house manufacturing facility in Houston, expanded research capacity and recruitment of additional scientific staff. The company completed several registered direct offerings, including raises of about $4 million in November, $1.5 million later that month and $1.7 million in December, and eliminated outstanding debt, strengthening its financial flexibility. FibroBiologics also appointed Jason D. Davis as CFO to guide finance, capital markets and SEC reporting as it scales operations.
On the clinical front, FibroBiologics said it finished and released master and working cell banks for its CYWC628 wound-healing programme under FDA cGMP standards, positioning it to begin its Phase 1/2 diabetic foot ulcer trial in Q1 2026 with interim data expected mid-year and topline results by year-end. The company also highlighted positive IND-enabling data for CYPS317 spheroids in psoriasis models leading to an IND filing on Dec. 30, 2025, and advancement of CYMS101 toward an IND submission for multiple sclerosis based on remyelination evidence.
Scientific achievements noted in the letter include confirmation of remyelination in brain repair models and promising results from a bone marrow organoid platform showing potential effects against tumor growth and age-related immune decline. The company said continued IP expansion included patents on methods for generating multipotent fibroblast-derived cells and approaches to modulate mitochondrial activity for aging therapies.
Looking ahead, FibroBiologics said 2026 will emphasise execution of planned clinical trials, continued IND submissions and strengthening its financial base to support research and development as it moves toward potential therapies for chronic and degenerative diseases.
